Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to boost lymphoma treatment

NCT ID NCT04884035

Ongoing Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-stage study tests whether adding either iberdomide or CC-99282 to standard chemotherapy (R-CHOP) can safely treat people with untreated aggressive B-cell lymphoma. About 224 adults will take part. The main goals are to find the best dose and check for side effects, while also looking at how well the tumors respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, B-CELL

Contacts and locations

Locations

  • Local Institution - 151

    Omaha, Nebraska, 68198, United States

  • Local Institution - 152

    Rochester, Minnesota, 55905-0001, United States

  • Local Institution - 154

    Scottsdale, Arizona, 85259, United States

  • Local Institution - 155

    Houston, Texas, 77003, United States

  • Local Institution - 159

    Kansas City, Kansas, 66160, United States

  • Local Institution - 160

    Jacksonville, Florida, 32224, United States

  • Local Institution - 161

    Marietta, Georgia, 30060, United States

  • Local Institution - 162

    Birmingham, Alabama, 35233, United States

  • Local Institution - 163

    Saint Louis Park, Minnesota, 55426, United States

  • Local Institution - 164

    Winston-Salem, North Carolina, 27157, United States

  • Local Institution - 166

    Wichita, Kansas, 67214, United States

  • Local Institution - 168

    Murray, Utah, 84107, United States

  • Local Institution - 169

    Duarte, California, 91010, United States

  • Local Institution - 170

    Charlotte, North Carolina, 28204, United States

  • Local Institution - 171

    St. George, Utah, 84790, United States

  • Local Institution - 200

    Salamanca, 37007, Spain

  • Local Institution - 201

    Barcelona, 08916, Spain

  • Local Institution - 203

    Málaga, 29010, Spain

  • Local Institution - 300

    Seoul, 06351, South Korea

  • Local Institution - 301

    Seoul, 3080, South Korea

  • Local Institution - 302

    Seoul, 138-736, South Korea

  • Local Institution - 400

    Taipei, 100229, Taiwan

  • Local Institution - 402

    Taichung, 407, Taiwan

  • Local Institution - 403

    Taichung, 40447, Taiwan

  • Local Institution - 501

    Adelaide, South Australia, 5000, Australia

  • Local Institution - 503

    Perth, WA 6000, Australia

  • Local Institution - 600

    Krakow, 30-727, Poland

  • Local Institution - 601

    Gdansk, 80-952, Poland

  • Local Institution - 602

    Warsaw, 02-781, Poland

  • Local Institution - 603

    Słomniki, 32-090, Poland

  • Local Institution - 604

    Wroclaw, 50-367, Poland

  • Local Institution - 605

    Skórzewo, Greater Poland Voivodeship, 60-185, Poland

  • Local Institution - 700

    Thessaloniki, 57010, Greece

  • Local Institution - 701

    Athens, 12464, Greece

  • Local Institution - 702

    Athens, 10676, Greece

  • Local Institution - 704

    Athens, 11 527, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.